Anavex Announces Positive Data for ANAVEX 2-73 in Alzheimer’s Disease

Data Presented at Society for Neuroscience 2013 Annual Meeting New York, NY — November 12, 2013 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL) is pleased to announce that new study data showed ANAVEX 2-73 to be effective in counteracting the progression of Alzheimer’s disease under chronic treatment in a transgenic mouse model…